| review article | Q7318358 |
| scholarly article | Q13442814 |
| opinion paper | Q92998777 |
| P2093 | author name string | Rudolf A. de Boer | |
| Anne E. de Leeuw | |||
| P2860 | cites work | Prediction of Coronary Heart Disease Using Risk Factor Categories | Q22241923 |
| Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies | Q24608301 | ||
| Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials | Q24628988 | ||
| Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q24642503 | ||
| Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial | Q27301948 | ||
| Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial | Q28168920 | ||
| Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria | Q28211392 | ||
| Active sugar transport in health and disease | Q28283298 | ||
| Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion | Q28286955 | ||
| Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting | Q28300488 | ||
| Angiotensin II-dependent increased expression of Na+-glucose cotransporter in hypertension | Q28565155 | ||
| Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney | Q28580452 | ||
| Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models | Q28732080 | ||
| Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. | Q51748822 | ||
| Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. | Q51763308 | ||
| Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. | Q52961670 | ||
| Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) | Q57245141 | ||
| Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial | Q57274347 | ||
| Type 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion | Q57303412 | ||
| Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study | Q57740599 | ||
| Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes | Q44947020 | ||
| Long-term outcome of renal glucosuria type 0: the original patient and his natural history | Q45010378 | ||
| Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia | Q45442620 | ||
| Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. | Q45990556 | ||
| Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models | Q46516165 | ||
| Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial | Q46595958 | ||
| Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes | Q46764321 | ||
| Importance of glucose control | Q46810804 | ||
| Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes | Q46818617 | ||
| Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes | Q47581268 | ||
| Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years | Q47871792 | ||
| A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes | Q47916425 | ||
| Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. | Q50448714 | ||
| Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. | Q51304272 | ||
| Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. | Q51359456 | ||
| Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. | Q51362851 | ||
| Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. | Q51369293 | ||
| Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. | Q51372081 | ||
| Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. | Q51610700 | ||
| Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study | Q41745784 | ||
| Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea | Q41759692 | ||
| Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. | Q41895967 | ||
| Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice | Q42006157 | ||
| SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function | Q42153763 | ||
| Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial | Q42706050 | ||
| Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial | Q42977455 | ||
| Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight | Q43046356 | ||
| Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study | Q43165555 | ||
| Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients | Q43203524 | ||
| Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. | Q43755014 | ||
| Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial | Q44251536 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| Glucose control and vascular complications in veterans with type 2 diabetes | Q29619213 | ||
| Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data | Q30612949 | ||
| Renal gluconeogenesis: its importance in human glucose homeostasis | Q32050169 | ||
| Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? | Q33354192 | ||
| Hyperglycemia and cardiovascular disease in type 2 diabetes | Q33637016 | ||
| The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus | Q33888236 | ||
| Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial | Q34008233 | ||
| SGLT2 inhibition--a novel strategy for diabetes treatment | Q34117872 | ||
| The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose | Q34121476 | ||
| Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial | Q34153496 | ||
| Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes | Q34227891 | ||
| Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications | Q34292429 | ||
| Dapagliflozin: a review of its use in type 2 diabetes mellitus | Q34313024 | ||
| Status of glucose transporters in the mammalian kidney and renal development | Q34333415 | ||
| The Sweet Pee model for Sglt2 mutation | Q34457273 | ||
| Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2 | Q34501684 | ||
| Arrhythmia susceptibility and myocardial composition in diabetes. Influence of physical conditioning | Q34520442 | ||
| The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity | Q34524690 | ||
| Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone | Q34543009 | ||
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
| Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis | Q34985373 | ||
| Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes | Q35043833 | ||
| Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members | Q35111563 | ||
| Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial | Q35179843 | ||
| Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose | Q35184196 | ||
| Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice | Q35194026 | ||
| Sodium cotransport proteins | Q35455322 | ||
| Dapagliflozin lowers plasma glucose concentration and improves β-cell function | Q35578244 | ||
| Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited | Q35671967 | ||
| SGLT-2 Inhibitors: A New Mechanism for Glycemic Control | Q35906490 | ||
| Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat | Q35950244 | ||
| Phlorizin: a review | Q35995949 | ||
| Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy | Q36047253 | ||
| Sympathetic overdrive and cardiovascular risk in the metabolic syndrome | Q36754316 | ||
| Fructose and uric acid in diabetic nephropathy | Q36782938 | ||
| Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. | Q36891945 | ||
| Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. | Q37219076 | ||
| Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial | Q37278239 | ||
| Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial | Q37279276 | ||
| A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment | Q37319128 | ||
| Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes | Q37325818 | ||
| Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes | Q37331262 | ||
| Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients | Q37524302 | ||
| Systematic review: glucose control and cardiovascular disease in type 2 diabetes | Q37557021 | ||
| The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus | Q37559421 | ||
| SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. | Q37575455 | ||
| Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. | Q37575461 | ||
| Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives | Q37590008 | ||
| Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. | Q37645623 | ||
| Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis | Q37698287 | ||
| Renal glucose reabsorption inhibitors to treat diabetes | Q37826538 | ||
| Pathophysiology of prediabetes | Q37833737 | ||
| Glucose handling by the kidney | Q37848041 | ||
| Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans | Q37848043 | ||
| SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. | Q37981884 | ||
| Effects of SGLT2 inhibitors on cardiovascular outcomes | Q37989674 | ||
| Diabetes and hypertension: the bad companions | Q38033768 | ||
| A new class of drug for the management of type 2 diabetes: sodium glucose co-transporter inhibitors: 'glucuretics'. | Q38064008 | ||
| The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). | Q38078661 | ||
| The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus | Q38112660 | ||
| Effects of dapagliflozin on cardiovascular risk factors | Q38113098 | ||
| Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: a translational perspective for the cardiologist. | Q38175148 | ||
| Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations | Q38175467 | ||
| Canagliflozin: a review of its use in patients with type 2 diabetes mellitus | Q38212007 | ||
| The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension | Q38306298 | ||
| Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study | Q38435071 | ||
| Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus | Q38439475 | ||
| Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes | Q38524435 | ||
| Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats | Q39999985 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | glucose | Q37525 |
| glycobiology | Q899224 | ||
| P304 | page(s) | 244-55 | |
| P577 | publication date | 2016-10-01 | |
| P1433 | published in | European heart journal. Cardiovascular pharmacotherapy | Q27726932 |
| P1476 | title | Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects | |
| P478 | volume | 2 |
| Q38712728 | Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes. |
| Q55384960 | Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts. |
| Q89273102 | Empagliflozin: A Review in Type 2 Diabetes |
| Q91802305 | European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure |
| Q90022466 | Figures of the Heart Failure Association (HFA): Dr. Rudolf de Boer, HFA Board Member (2014-2020), Chair of the Basic Science Section (2016-2018), coordinator of the Study Group on Heart Failure with Preserved Ejection Fraction, and member of the HFA |
| Q57094316 | Focusing on Sodium Glucose Cotransporter-2 and the Sympathetic Nervous System: Potential Impact in Diabetic Retinopathy |
| Q39164190 | Integrated cardiovascular safety: multifaceted considerations in drug development and therapeutic use. |
| Q50067957 | Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy |
| Q94464323 | Prospect of Sodium-Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes |
| Q47614541 | Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials |
| Q96954240 | Sodium glucose co-transporter-2 inhibitors in heart failure: beyond glycaemic control. The Position Paper of the Heart Failure Association of the European Society of Cardiology |
| Q92475887 | Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes? |
| Q91593292 | Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction |
| Q64091931 | Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments |
| Q88013533 | The impact of oral anti-diabetic medications on heart failure: lessons learned from preclinical studies |
| Q49547336 | Type 2 Diabetes and Heart Failure - More Scrutiny Wanted! |
Search more.